Vident Investment Advisory’s AtriCure ATRC Stock Holding History

Vident Investment Advisory’s Portfolio ATRC Stock Details ATRC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-23,967	Closed	-$648K	–	927
2018 Q2	$648K	Sell	23,967 -4,722	-16%	-$111K	0.03%	555
2018 Q1	$607K	Buy	28,689 +1,165	+4%	+$21K	0.02%	532
2017 Q4	$502K	Buy	+27,524	New	+$545K	0.02%	566
2017 Q2	–	Sell	-16,881	Closed	-$323K	–	440
2017 Q1	$323K	Buy	+16,881	New	+$296K	0.03%	364
2016 Q3	–	Sell	-44,488	Closed	-$629K	–	395
2016 Q2	$629K	Sell	44,488 -76,058	-63%	-$1.16M	0.09%	351
2016 Q1	$2.03K	Buy	120,546 +59,931	+99%	+$1.05M	0.13%	302
2015 Q4	$1.36M	Sell	60,615 -17,851	-23%	-$368K	0.17%	273
2015 Q3	$1.72M	Buy	+78,466	New	+$1.96M	0.24%	115

Other funds holding ATRC

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HEC

Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Vident Investment Advisory's ATRC Position: Q3 2018 in Review

Vident Investment Advisory sold out of AtriCure (ATRC) in Q3 2018, closing a stake of 23,967 shares — an estimated $648K sold.

Vident Investment Advisory first reported a position in ATRC in Q3 2015 and held it in 8 quarters. The position peaked at $1.72M in Q3 2015. 126 funds tracked by Wall St. Rank hold ATRC as of Q3 2018.

Vident Investment Advisory reported no remaining AtriCure position as of Q3 2018 after selling out during the quarter.
Vident Investment Advisory sold 23,967 AtriCure shares in Q3 2018, an estimated $648K.
Vident Investment Advisory first reported a position in AtriCure in Q3 2015 and held it in 8 quarters.
Vident Investment Advisory's AtriCure position peaked at $1.72M in Q3 2015.
126 funds tracked by Wall St. Rank held AtriCure as of Q3 2018.

Based on Vident Investment Advisory's 13F filing for Q3 2018, filed 14 Nov 2018.